Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

T cells engineered to express CD19-specific chimeric antigen receptors (CARs) have shown breakthrough clinical successes in patients with B-cell lymphoid malignancies. However, similar therapeutic efficacy of CAR T cells in solid tumors is yet to be achieved. In this study we systematically evaluate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hum Gene Ther
Autores principales: Li, Wenpeng, Guo, Linjie, Rathi, Purva, Marinova, Ekaterina, Gao, Xiuhua, Wu, Meng-Feng, Liu, Hao, Dotti, Gianpietro, Gottschalk, Stephen, Metelitsa, Leonid S., Heczey, Andras
Formato: Artigo
Lenguaje:Inglês
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Review Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5444493/
https://ncbi.nlm.nih.gov/pubmed/27530312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2016.025
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares